VGXI v. Aldevron: Biomaterial Production Patent Case Stayed Pending Arbitration
VGXI, Inc. sued Aldevron LLC in the Texas Southern District Court for alleged infringement of US7238522B2, covering devices and methods for biomaterial production. The case was stayed pending arbitration and administratively closed without prejudice — a resolution that left the merits unresolved after more than 1,200 days on the docket.
Biomaterial IP dispute diverted to arbitration after three years
On December 6, 2019, VGXI, Inc. filed a patent infringement action against Aldevron LLC in the United States District Court for the Southern District of Texas, asserting US7238522B2, which covers devices and methods for biomaterial production. The case was assigned to Judge Drew B. Tipton and prosecuted by Blank Rome LLP for the plaintiff, with a substantial defence team led by Williams & Connolly LLP and WilmerHale for the defendant.
The recorded basis of termination is 'Case Stayed.' The docket order states that on March 21, 2021, Judge Lynn Hughes stayed the case pending arbitration (Dkt. No. 82), and that the civil action remains stayed and shall be administratively closed without prejudice to it being reopened upon a motion by any party.
See Complete Case & Patent Analysis →Filing to Case Stayed in 1215 days
days from filing to administrative closure — over three years on the docket
US7238522B2 — Devices and methods for biomaterial production
Any organisation involved in contract manufacturing, internal production, or tooling of biomaterials — particularly plasmid DNA, mRNA constructs, or recombinant proteins — should assess exposure to US7238522B2. The patent remains active and its merits were never adjudicated in this proceeding. CDMOs, gene therapy developers, and biopharma in-house manufacturing teams are the most directly affected stakeholders.
Official order — verbatim text
The docket order staying this case reflects a judicial determination that a valid arbitration agreement governed the dispute between VGXI and Aldevron, diverting the infringement claims from the federal merits track. No liability finding, invalidity ruling, or damages determination was made; the merits of US7238522B2 remain unresolved in the public record.
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | VGXI, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Aldevron LLC | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Daniel E. Rhynhart | Attorney | Counsel for VGXI, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel S. Morris | Attorney | Counsel for VGXI, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Domingo Manuel LLagostera | Attorney | Counsel for VGXI, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert Philip Scott | Attorney | Counsel for VGXI, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Blank Rome LLP | Law Firm | Representing VGXI, Inc.Search in Eureka ↗ |
| Defendant counsel | Cecil Bryan Wilson | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | Dane H. Butswinkas | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | David S. Blatt | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | Dov P. Grossman | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | Emily R. Whelan | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | Jesus David Cabello | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | John M. Hintz | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | John P. Hanish | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | Kevin J. Culligan | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | Robert M. Galvin | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant counsel | William F. Lee | Attorney | Counsel for Aldevron LLCSearch in Eureka ↗ |
| Defendant law firm | Cabello Hall Zinda PLLC | Law Firm | Representing Aldevron LLCSearch in Eureka ↗ |
| Defendant law firm | Maynard, Cooper & Gale, PC | Law Firm | Representing Aldevron LLCSearch in Eureka ↗ |
| Defendant law firm | Williams & Connolly LLP | Law Firm | Representing Aldevron LLCSearch in Eureka ↗ |
| Defendant law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Aldevron LLCSearch in Eureka ↗ |
| Presiding judge | Judge Drew B Tipton | Judge | Texas Southern District CourtSearch in Eureka ↗ |
R&D signals in the biomaterial and nucleic acid production IP space
Forward-looking patent intelligence derived from the VGXI v. Aldevron dispute — mapping filing trends, portfolio gaps, and competitive positioning in biomaterial production.
VGXI's IP footprint in biomaterial and nucleic acid production
VGXI's assertion of US7238522B2 against a leading CDMO suggests a deliberate enforcement posture. Mapping VGXI's broader filing activity around biomaterial production devices, upstream bioprocessing, and nucleic acid yield optimisation could reveal additional patents that CDMOs and gene therapy manufacturers need to monitor.
Plaintiff portfolio watchFiling trends in plasmid DNA and gene therapy manufacturing
The intersection of plasmid DNA production, fermentation scale-up, and purification technologies is attracting dense patent filing activity as gene therapy and mRNA therapeutics expand. Understanding claim density in this space helps manufacturers identify freedom-to-operate risks and spot under-protected sub-technologies ripe for internal R&D investment.
Sector filing trendsAldevron's patent position in nucleic acid contract manufacturing
Aldevron's deployment of a multi-firm defence team signals that the disputed production methods are commercially significant to its operations. Tracking Aldevron's own patent filings and any defensive publications in nucleic acid purification and bioprocessing provides intelligence on how it is building IP insulation around its manufacturing platform.
Defendant IP watchAdjacent white space in biomaterial device and process engineering
Claims around biomaterial production devices — as opposed to the biological molecules themselves — represent a distinct and often less crowded IP layer. Engineering teams developing novel bioreactor configurations, membrane-based separation systems, or continuous bioprocessing apparatus for nucleic acid production may find meaningful white space adjacent to the US7238522B2 claim scope.
White-space R&D signalSimilar patent infringement cases in biomaterial and nucleic acid production
Cases involving biomaterial and nucleic acid production patents in US district courts, where manufacturing method claims intersect with CDMO and gene therapy workflows.
What this case signals for the biomaterial production IP landscape
A court-ordered stay pending arbitration suggests a pre-existing contractual relationship between VGXI and Aldevron that the public record does not fully disclose.
Arbitration clauses can redirect patent disputes away from federal courts
The stay order indicates the court found a valid arbitration agreement between the parties. Companies engaging in biomaterial production contracts should audit whether their agreements include arbitration clauses that could pull infringement claims out of district court — altering timelines, discovery scope, and enforceability of any award.
Administrative closure without prejudice keeps the litigation door open
The order explicitly preserves the right of either party to reopen proceedings. For US7238522B2, this means the patent's enforceability through federal litigation has not been tested on the merits. Competitors and licensees should treat the patent as fully active and potentially enforceable.
VGXI v Aldevron — key questions answered
VGXI, Inc. sued Aldevron LLC in the Texas Southern District Court for patent infringement of US7238522B2, which covers devices and methods for biomaterial production. The case was filed in December 2019 and stayed pending arbitration in March 2021, then administratively closed without prejudice.
On March 21, 2021, Judge Lynn Hughes ordered the case stayed pending arbitration (Dkt. No. 82). A stay of this nature typically indicates the court determined a valid arbitration agreement existed between the parties. The specific terms of any such agreement are not disclosed in the available public record.
Administrative closure without prejudice means the case is removed from the active docket but has not been dismissed on the merits. Either party may file a motion to reopen the case. The merits of the infringement claims and the validity of US7238522B2 were not adjudicated in this proceeding.
The administrative closure did not result in any invalidity finding or unenforceability ruling. No merits determination was made. As a result, US7238522B2 remains in force and companies operating in the biomaterial and nucleic acid production space should continue to treat it as potentially enforceable.
VGXI was represented by Blank Rome LLP. Aldevron retained four firms: Cabello Hall Zinda PLLC, Maynard Cooper & Gale PC, Williams & Connolly LLP, and WilmerHale. The scale of Aldevron's defence team is consistent with significant commercial stakes in the disputed biomaterial production technology.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.